Clinical Trial Update: Dovitinib in Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of dovitinib in neuroendocrine tumors (paraganglioma and pheochromocytoma) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Advanced Metastatic Paraganglioma, Advanced Metastatic Pheochromocytoma | Phase 2 | Status: COMPLETED